CT101A

CT101A (also known as WU-NK-101) is an allogeneic, off-the-shelf, non-genetically engineered (non-GE) natural killer (NK) cell therapy. Developed by Wugen and licensed to Alpha Biopharmaceuticals for development in Greater China, the therapy utilizes "memory-like" NK cells. These cells are cytokine-induced (typically using a cocktail of IL-12, IL-15, and IL-18) to exhibit enhanced effector function, increased persistence, and superior metabolic fitness compared to conventional NK cells. CT101A is currently being evaluated in Phase 1 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML), including in haploidentical donor settings, and is also being explored for potential applications in solid tumors.

Other names

WU-NK-101WU-NK101WU-NK 101Memory-like NK cellsML-NK cells